Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-17 RA

IL-17 RA

Brief Information

Name:Interleukin-17 receptor A
Target Synonym:CDw217,IL-17 receptor A,IL17R,IL17RA,Interleukin 17 Receptor A,IL-17RA,Interleukin 17 Receptor,CD217 Antigen,HIL-17R,CANDF5,CD217,IMD51,Interleukin-17 receptor A
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data


Loaded Biotinylated Human IL-17 RA, Fc,Avitag (Cat. No. ILA-H82F1) on SA Biosensor, can bind Human IL17A, Tag Free (Cat. No. ILA-H5118) with an affinity constant of 1.29 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Human IL-17 RA, Fc Tag (Cat. No. ILA-H5257) on Protein A Biosensor, can bind Human IL17A, Tag Free with an affinity constant of 0.21 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Interleukin 17 receptor A (IL17RA) is also known as cluster of differentiation w217 (CDw217), is a pro-inflammatory cytokine secreted by activated T-lymphocytes, belong to ubiquitous type I membrane glycoprotein, and binds with low affinity to interleukin 17A (IL17A). IL 17R mRNA exhibits a broad tissue distribution, and has been detected in virtually all cells and tissues tested . IL 17RA associates with IL 17RC to form a signaling receptor complex for IL 17 and IL 17F . Ligand and IL 17RA ligation promotes T cell activation and the production of IL - 6, G-CSF, SCF, and multiple pro-inflammatory chemokines. Defects in IL17RA are the cause of familial candidiasis type 5 (CANDF5).

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Brodalumab IL-17R mAb; MEDI-6365; KHK-4827; AMG-827 Approved Amgen Inc Siliq, Lumicef, Kyntheum, 立美芙 Mainland China Plaque psoriasis Kyowa Kirin 2016-07-04 Arthritis, Rheumatoid; Spondylitis, Ankylosing; Scleroderma, Systemic; Psoriasis; Asthma; Arthritis, Psoriatic; Crohn Disease; Plaque psoriasis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LY-3114062 LY3114062; LY-3114062 Phase 1 Clinical Eli Lilly And Company Arthritis Details
S-011806 S-011806 Phase 1 Clinical Psoriasis Details
XCUR-17 XCUR-17 Phase 1 Clinical Exicure Psoriasis Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message